Dangerous Ignorance: What Patients Don’t Understand about Pharmacogenomics
Indiana UniversityDo you know what pharmacogenomics is? You might not, but you should, and all patients should.
Do you know what pharmacogenomics is? You might not, but you should, and all patients should.
A new multi-site study led by Indiana University School of Medicine found increasing pediatric readiness in emergency departments reduces, but does not eliminate, racial and ethnic disparities in children and adolescents with acute medical emergencies.
Public sector should pay if EU demands efficient removal of pharmaceuticals from wastewaters, according to researchers at the Centre for Antibiotic Research, CARe, at the University of Gothenburg.
A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a new study finds.
إن تلقي لقاح كوفيد-19 قد لا يُقلِّل فقط من خطر إصابة الشخص بكوفيد طويل الأمد، ولكنه قد يعني أيضًا أعراضًا أقل للأشخاص الذين يُصابون بهذه الحالة.
Tomar a vacina contra COVID-19 pode não só reduzir os riscos de uma pessoa contrair COVID de longa duração, mas também pode significar a redução dos sintomas para a pessoa que desenvolver a doença.
University of Illinois researchers and a Swiss pharmaceutical company have developed a machine learning model that eliminates the need for extensive experimentation to determine the best conditions for an important carbon-nitrogen bond forming reaction known as the Buchwald-Hartwig reaction.
Although the COVID-19 pandemic was the first time most of humanity learned of the now infamous disease, the family of coronaviruses was first identified in the mid-1960s.
“We find that people who are in better shape fill fewer prescriptions for anxiety and depression medications,” says Linda Ernstsen, the senior author of the article and an associate professor from the Department of Public Health and Nursing at the Norwegian University of Science and Technology (NTNU).
People who have had a stroke called an intracerebral hemorrhage who take cholesterol-lowering drugs called statins may have a lower risk of having another stroke, especially ischemic stroke, compared to people who also had an intracerebral hemorrhage but were not taking statins, according to a new study published in the August 30, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
The COVID-19 pandemic made it very clear that we need better methods to quickly screen for dangerous pathogens and substances.
A new opinion piece published in Health Affairs Forefront raises questions around current approaches to assess drug safety and effectiveness in people with obesity.
A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists, and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RA’s) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children’s health.
A new drug offers a breakthrough world first treatment for Lipoprotein(a), a largely genetic form of cholesterol that increases the risk of heart attack and stroke, announced today by study lead Professor Stephen Nicholls, Director of the Monash University’s Victorian Heart Institute and Victorian Heart Hospital.
Researchers at Saint Louis University School of Medicine say diagnostic delays frequently occur in patients with undiagnosed head and neck cancer (HNC) and are calling for improved dissemination of current clinical practice guidelines in a new paper published Aug. 24 in JAMA Otolaryngology – Head & Neck Surgery.
Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
Acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are recommended as first-line treatments for managing short-term dental pain in children under age 12, according to a new clinical practice guideline.
A new fund to fast-track patient access to potentially valuable new medicines may incentivise the pharmaceutical industry to develop high priced drugs for rare diseases with weak evidence on clinical benefits.
In 2017, the teams of Massimo Terzolo and Martin Fassnacht published a study in the New England Journal of Medicine that provided evidence for the efficacy of Mitotane in the prevention of recurrence in adrenocortical carcinoma.
The U.S. Food and Drug Administration is approving more novel pharmaceutical drugs based on single clinical trials and with less public disclosure about those trials than was the norm just a few years ago, a pair of recent studies from Oregon State University found.
Altis Biosystems, a leader in developing innovative, in vitro cell-based model systems for drug discovery, announces the launch of RepliGut® Planar InflammaScreen™ Services.
A research team led by University of California, Irvine scientists has developed an innovative method for quickly and efficiently creating vast collections of chemical compounds used in drug discovery by harnessing the power of ribosomes, the molecules found in all cells that synthesize proteins and peptides.
En julio, salió al mercado el primer análisis de sangre directo al consumidor diseñado para evaluar el riesgo de un usuario de desarrollar la enfermedad de Alzheimer.
The science is unclear on exactly why an increasingly popular new class of federally approved diabetes and obesity medications work, but they do know that they are effective at helping people lose weight.
In July, the first direct-to-consumer blood test designed to assess a user’s risk for developing Alzheimer’s disease hit the market.
Huntsman Cancer Institute researchers studied estrogen receptor mutations and its connections to endometrial cancer. The findings led to the identification of potential personalized treatments for a cancer with limited options.
The world needs greener ways to make chemicals. In a new study, University of Wisconsin–Madison researchers demonstrate one potential path toward this goal by adapting hydrogen fuel cell technologies.
Clopidogrel is a commonly prescribed medication used to prevent further heart attacks after an initial event. It needs to be activated in the body to be effective.
Scientists at St. Jude Research Hospital unravel the mechanisms behind a key culprit in chemotherapy resistance.
Artificial intelligence's impact goes beyond clinical medicine. It is reshaping science in more profound ways.
Rutgers scientists have devised a highly accurate method for creating coatings of biologically active materials for a variety of medical products. Such a technique could pave the way for a new era of transdermal medication, including shot-free vaccinations, the researchers said.
In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making Rexulti the first antipsychotic for treating agitation in elderly patients with dementia.
Bacteria draw from an arsenal of weapons to combat the drugs intended to kill them. Among the most prevalent of these weapons are ribosome-modifying enzymes. These enzymes are growing increasingly common, appearing worldwide in clinical samples in a range of drug-resistant bacteria.
David Julius, PhD, who received the Nobel Prize in Medicine in 2021, has been selected to receive ASRA Pain Medicine’s 2023 John J. Bonica Award. He will present the annual lecture on Saturday, November 11, in conjunction with the 22nd Annual Pain Medicine Meeting in New Orleans, LA.
ISPOR—The Professional Society for Health Economics and Outcomes Research published a new ISPOR Report that provides an overview of gaps and challenges in the value assessment of biosimilars and identifying potential approaches to address them. The report was published in the August 2023 issue of Value in Health.
A clinical trial evaluating the role of statins in the risk of recurrent intracerebral hemorrhage (ICH) in patients presenting with ICH, has opened for enrollment at UTHealth Houston.
The American Society for Pharmacology and Experimental Therapeutics (ASPET) has automated its Automated Patient-Oriented Problem-Solving (A-POPS) learning tool.
AASLD, ACG, AGA, ASGE and NASPGHAN recognize that the new class of GLP-1 receptor agonist may be associated with delayed gastric emptying and encourage our anesthesiology, endocrinology, and industry partners to work collaboratively with our members to develop the necessary evidence to appropriately inform medication adjustments prior to elective endoscopy.
Over 50 million K-12 students across the United States will return to classrooms this month, according to the National Center for Education Statistics. Michigan State University experts provide guidance on how to ensure students are physically and mentally prepared for the new school year.
A collaborative study undertaken by the Navarrabiomed Biomedical Research Center (Pamplona, Navarre), the Institute of Neurosciences CSIC-UMH (Sant Joan d’Alacant, Valencian Community) and IRB Barcelona (Barcelona, Catalonia) shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease.
A new study of mice and lab-grown human colon “organoids” indicates that an experimental drug developed by Johns Hopkins Medicine researchers can substantially reduce symptoms of inflammatory bowel disease (IBD) in pre-clinical models.
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform today announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company for the Middle East and North Africa (MENA).
People who take acid reflux medications called proton pump inhibitors for four-and-a-half years or more may have a higher risk of dementia compared to people who do not take these medications, according to new research published in the August 9, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. This study does not prove that acid reflux drugs cause dementia; it only shows an association.
In a recent study, Illinois Sustainable Technology Center environmental chemist Wei Zheng and colleagues investigated the adsorption of sitagliptin in soils treated with sewage wastewater.